Home ::> Staff Listings ::> Staff Listing by Name ::> R ::> Peter Rieckmann
STAFF LISTING
Dr. Peter Rieckmann, MD FRCPC
Professor of Neurology
Multiple Sclerosis Society of Canada Research Chair
Director of MS Program at University of British Columbia
Division of Neurology, Dept. of MedicineAddresses:
2211 Wesbrook Mall, Room S192
Vancouver BC Canada V6T 2B5Tel: 604-827-3111
Email: prieckmann@brain.ubc.ca
Research Interests:
Multiple sclerosis (pathogenesis, immunology, regeneration and new treatment srategies
Pathopyhsiology and treatment of neuroimmunological disorders
Molecular and functional aspects of blood brain barrier disturbances in neurological diseases
Professional Training:
1982 – 1988
Medical school (University of Göttingen)
1987 – 1988
Clinical Internship and Elective, Institue of Neurology (National Hospital Queen Square, London GB)
1989 – 1990
Attending Clinical Scientist AIDS Clinical and Vasculitis, Dr. A. Fauci, NIAID, NIH (Bethesda, USA)
1991 – 1995
Resident in Clinical Neurology (University of Göttingen)
Academic Positions:
1995
Assistant Professor, Department of Neurology (University of Göttingen)
1996 – 2001
Assistant Professor, Department of Neurology (University of Würzburg)
2001 – 2003
Associate Professor Department of Neurology (University of Würzburg)
2004 - Present
Professor for Clinical Neuroscience, Department of Neurology (University of Würzburg)
2006
Visiting professor McGill university (Montreal), University of Nagoya (Japan) and University school of Belgrade (Serbia)
2007
Visiting professor University Med. School of Chennai (India)
2007
Multiple Sclerosis Society of Canada Research Chair (UBC), Director MS Program at UBC and VCH
2007
Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC)
Honours and Awards:
Student fellowship from Carl-Duisberg-Stiftung
Student research fellowship Max-Planck Society (India)
Young investigator award (German Society for Clinical Chemistry)
Gerhard-Hess-fellowship (German Research Association)
Langheinrich-Prize for Multiple-Sclerosis-Research
Käte-Hammersen-Prize (German Multiple Sclerosis Society)
Award of the medical faculty for the best Habilitation thesis (University Göttingen)
Hans-Heinrich-Queckenstedt-Prize
Wartenberg-Lecture (German Neurological Association)
Board Representations:
European Committee for Trials and Research in MS (ECTRIMS)
Medical Advisory Board of the Multiple Sclerosis International Federation (MSIF)
Medical Advisory Board of the German MS Society (DMSG)
Steering committee European Multiple Sclerosis Therapy Consensus Group
Steering committee of various international multi-center MS trials (Phase II and III)
Regional Director and MS initiative of the Canadian Multiple Sclerosis Society
Publications
Multiple Sclerosis Therapy Consensus Group (MSTCG):
Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations.
J Neurol. 2008. Oct;255(10):1449-63. [PubMed]Rieckmann P, Traboulsee A, Devonshire V, Oger J. Escalating Immunotherapies for Multiple Sclerosis. Therapeutic Advances in Neurological Disorders. 2008 1(3) 181–192.
Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K; PRIVIG Study Group; UBC MS/MRI Research Group. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology. 2008 Jul 22;71(4):265-71. [PubMed]
Rieckmann P. Imatinib buys time for brain after stroke. Nat Med. 2008 Jul;14(7):712-3. [PubMed]
International Multiple Sclerosis Genetics Consortium (IMSGC). Refining genetic associations in multiple sclerosis. Lancet Neurol. 2008 Jul;7(7):567-9. [PubMed]
Ruprecht K, Gronen F, Sauter M, Best B, Rieckmann P, Mueller-Lantzsch N. Lack of immune responses against multiple sclerosis-associated retrovirus/human endogenous retrovirus W in patients with multiple sclerosis. J Neurovirol. 2008 Apr;14(2):143-51. [PubMed]
Buttmann M, Rieckmann P. Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother. 2008 Mar;8(3):433-55. Review. [PubMed]
Yu X, Koczan D, Sulonen AM, Akkad DA, Kroner A, Comabella M, Costa G, Corongiu D, Goertsches R, Camina-Tato M, Thiesen HJ, Nyland HI, Mørk SJ, Montalban X, Rieckmann P, .Ibrahim SM. mtDNA nt13708A variant increases the risk of multiple sclerosis.PLoS ONE. 2008 Feb 13;3(2):e1530. [PubMed]
Buttmann M, Merzyn C, Hofstetter HH, Rieckmann P. TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol. 2007 Oct;190(1-2):170-6. Epub 2007 Sep 19. [PubMed]
Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract. 2007 Nov;61(11):1922-30. Epub 2007 Sep 3. Review. [PubMed]
Buttmann M, Lorenz A, Weishaupt A, Rieckmann P. Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration. J Neurochem. 2007 Aug;102(4):1001-8. Epub 2007 Apr 17. [PubMed]
Buttmann M, Rieckmann P. Interferon-beta1b in multiple sclerosis. Expert Rev Neurother. 2007 Mar;7(3):227-39. Review. [PubMed]
Buttmann M, Berberich-Siebelt F, Serfling E, Rieckmann P. Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells. J Vasc Res. 2007;44(1):51-60. Epub 2006 Dec 13. [PubMed]
Gronen F, Ruprecht K, Weissbrich B, Klinker E, Kroner A, Hofstetter HH, Rieckmann P. Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls. J Neuroimmunol. 2006 Nov;180(1-2):185-92. Epub 2006 Oct 4. [PubMed]
Henze T, Rieckmann P, Toyka KV; Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78-105. Epub 2006 Sep 8. [PubMed]
Ruprecht K, Obojes K, Wengel V, Gronen F, Kim KS, Perron H, Schneider-Schaulies J, Rieckmann P. Regulation of human endogenous retrovirus W protein expression by herpes simplex virus type 1: implications for multiple sclerosis.
J Neurovirol. 2006 Feb;12(1):65-71. [PubMed]
Kallmann BA, Fackelmann S, Toyka KV, Rieckmann P, Reiners K. Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler. 2006 Feb;12(1):58-65. [PubMed]
Buttmann M, Goebeler M, Toksoy A, Schmid S, Graf W, Berberich-Siebelt F, Rieckmann P. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J Neuroimmunol. 2005 Nov;168(1-2):175-82. Epub 2005 Aug 26. [PubMed]
Kroner A, Mehling M, Hemmer B, Rieckmann P, Toyka KV, Mäurer M, Wiendl H. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol. 2005 Jul;58(1):50-7. [PubMed]
